aod 9604 vs semaglutide
updated
aod 9604 (tier D) vs semaglutide (tier S): what each is, half-life and source counts side by side.
aod 9604 · tier D
HGH fragment. went to phase 2b for obesity. failed. the data says it doesn't work.
tier rationale
D-tier because the compound has the best human clinical data in its class and the data shows it doesn't work meaningfully for weight loss. Not F-tier because the compound is real, safe, and does what it claims pharmacologically (isolated lipolytic activity without broader GH effects). The problem is that the magnitude is too small to matter. This is the tier for 'we tested it properly and it failed.' It's more respectful than F-tier and more accurate than C-tier. The GLP-1 revolution has made the entire premise obsolete regardless.
semaglutide · tier S
A GLP-1 receptor agonist with current US injection and oral products for distinct labeled uses.
tier rationale
The S tier reflects large randomized trials showing weight-loss, cardiovascular, and kidney benefits in the studied populations, plus positive biopsy outcomes in a planned phase 3 liver-disease interim analysis.
at a glance
| aod 9604 | semaglutide | |
|---|---|---|
| tier | D | S |
| category | weight loss / gh / growth | weight loss |
| sources | 16 | 16 |
| claims evaluated | 6 | n/a |
| half-life | plasma half-life extended versus unmodified fragment; lipolytic effects acute and dose-dependent | ~1 week |
| dosing data | yes | yes |
reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.